Role of molecular biology in the follow-up of patients who have Barrett's esophagus

Chest Surgery Clinics of North America

Volumn 12, Issue 1, 2002, Pages 93-111

  Casson, Alan G ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; PROTEIN P14; PROTEIN P16; PROTEIN P53;

ANEUPLOIDY; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CELL CYCLE; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; FOLLOW UP; HEREDITY; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; ONCOGENE NEU; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RISK ASSESSMENT; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0036188141     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00068-1     Document Type: Review

References (146)

1. Esophageal cancer and amplification of the human cyclin D gene CCND1/PRAD 1
2. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinoma
3. Allelotype study of esophageal carcinoma
4. Increased expression of the cyclin D1 gene in Barrett's esophagus
5. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats
6. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
7. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus
8. Allelic loss and mutational analysis of the DPC 4 gene in esophageal adenocarcinoma
9. p14ARF links the tumor suppressors Rb and p53
10. p53 mutation and protein accumulation during multistage esophageal carcinogenesis
11. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
12. Continuing climb in rates of esophageal adenocarcinoma: An update
13. The changing epidemiology of esophageal cancer
14. Clonal ordering of 17p and 5q allelic losses in Barrett's dysplasia and adenocarcinoma
15. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy
16. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers
17. The histidine triad superfamily of nucleotide-binding proteins
18. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
19. Barrett's esophagus: Age, prevalence and extent of columnar epithelium
20. p53 is frequently mutated in Barrett's metaplasia of the intestinal type
21. p53 gene mutations in Barrett's epithelium and esophageal cancer
22. Oncogene activation in esophageal cancer
23. Ras mutation, and expression of the ras regulated genes osteopontin and cathepsin L, in human esophageal cancer
24. Molecular biology of Barrett's esophagus and esophageal cancer: Role of p53
25. p53 Alterations in esophageal cancer: Association with clinicopathologic features and survival
26. Prognostic value of DNA index, S-phase fraction and p53 protein accumulation after surgical resection of esophageal squamous cell carcinoma in Thailand
27. The retinoblastoma protein as a fundamental mediator of growth and differentiation signals
28. Aberrant FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract
29. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
30. Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma
31. Familial gastroesophageal reflux and development of Barrett's esophagus
32. Columnar mucosa and intestinal metaplasia of the esophagus
33. Barrett's esophagus
34. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
35. The rising incidence of gastric cardia cancer
36. Allelotype analysis of esophageal adenocarcinoma: Loss of heterozygosity occurs at multiple sites
37. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus
38. WAF 1, a potential mediator of p53 tumor suppression
39. Low frequency of p16/CDKN 2 gene mutations in esophageal carcinomas
40. The cell cycle and the retinoblastoma protein family
41. Induction of cyclin D 1 overexpression by activated ras
42. Overexpression of p53 protein in Barrett's syndrome with malignant transformation
43. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations
44. Genome screening by comparative genomic hybridization
45. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
46. Barrett's esophagus in sexagenarian identical twins
47. Proliferating cell nuclear antigen in the assessment of Barrett's mucosa
48. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma
49. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma
50. Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia
51. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the esophagus and gastric cardia
52. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen
53. Mutation analysis of the p53, APC, and p16 genes in Barrett's esophagus, dysplasia and adenocarcinoma
54. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
55. Barrett's esophagus, dysplasia and adenocarcinoma
56. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualization tools
57. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus
58. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's esophagus
59. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
60. Frequent mutation of the p53 gene in human esophageal cancer
61. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus
62. Basic science of HER-2/neu: A review
63. Prognostic significance of transforming growth factor alpha in human esophageal carcinoma: Implication for the autocrine proliferation
64. Oncogenes and onco-suppressor genes in adenocarcinoma of the esophagus
65. Proliferating cell nuclear antigen in esophageal disease: Correlation with transforming growth factor alpha expression
66. Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases
67. Molecular evolution of the metaplasiadysplasia-adenocarcinoma sequence in the esophagus
68. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer
69. Familial Barrett's esophagus associated with adenocarcinoma
70. Close mapping of the focal non-epidermolytic palmoplantar keratoderma (PPK) locus associated with esophageal cancer (TOC)
71. Tumor suppressor p53: Implications for tumor development and prognosis
72. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma
73. Barrett's esophagus in a patient with surgically treated achalasia
74. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus
75. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
76. Association between body mass and adenocarcinoma of the esophagus and gastric cardia
77. Cellular kinetics in Barrett's epithelium carcinogenic sequence: Role of apoptosis, bcl-2 protein, and cellular proliferation
78. Convergence of mitotic signaling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb controlled G1 checkpoint
79. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus
80. Barrett's esophagus with adenocarcinoma in scleroderma
81. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's associated esophageal adenocarcinomas
82. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia
83. WAF1/CIP1/SD11 gene products in Barrett's esophagus and adenocarcinoma of the esophagus and esophagogastric junction
84. Barrett's esophagus following total gastrectomy
85. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas
86. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review
87. Prognostic value of DNA ploidy and c-erb-B2 oncoprotein expression in adenocarcinoma of Barrett's esophagus
88. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia
89. Common deleted region of the long arm of chromosome 5 in esophageal carcinoma
90. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus
91. The histopathology and biologic prognostic factors of Barrett's esophagus
92. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations
93. p19ARF links the tumor suppressor p53 to ras
94. Barrett's esophagus with high-grade dysplasia: An indication for esophagectomy?
95. Epithelial cell hyperproliferation after biliopancreatic reflux into the esophagus of rats
96. Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer
97. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction
98. Familial cancer of the esophagus in Iran
99. APC gene mutations in the mutation cluster region are rare in esophageal cancers
100. The p53 pathway
101. Persistent clonal areas and clonal expansion in Barrett's esophagus
102. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
103. Barrett's esophagus: Ordering the events that lead to cancer
104. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
105. The tylosis esophageal cancer (TOC) locus: More than just a familial cancer gene
106. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wildtype p53
107. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma
108. The cell and molecular biology of esophageal carcinoma
109. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus
110. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia
111. Biomarkers for malignancy in the columnar-lined esophagus
112. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus
113. The prognostic significance of DNA ploidy in adenocarcinomas of the esophagogastric junction
114. Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): An iatrogenic injury?
115. The prognostic significance of tumor ploidy and pathology in adenocarcinoma of the esophagogastric junction
116. Mutations of p53 in Barrett's esophagus and Barrett's cancer: A prospective study of 98 cases
117. INK4
118. Role of reflux esophagitis and acid in the development of columnar epithelium in the rat esophagus
119. Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology
120. Carcinoma of the esophagus with tylosis
121. Classification of adenocarcinomas of the oesophagogastric junction
122. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: A prospective study
123. The molecular basis for carcinogenesis in metaplastic columnarlined esophagus
124. Barrett's epithelium complicating lye ingestion with sparing of the distal esophagus
125. Prevalence of metaplasia at the gastrooesophageal junction
126. Endoscopic surveillance of Barrett's esophagus. Does it help?
127. Barrett's esophagus and esophageal cancer
128. Endoscopic surveillance of Barrett's esophagus: A cost-effective comparison with mammographic surveillance for breast cancer
129. Altered p16/MTS/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus
130. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia
131. Barrett's esophagus: Disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasis-carcinoma sequence
132. The neoplastic potential of columnar-lined (Barrett's) esophagus
133. Endoscopic features of the columnar-lined esophagus
134. Comparative genomic hybridization of cancer of the gastroesophageal junction: Deletion of 14q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas
135. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma
136. Clinical implications of p53 mutations
137. Apoptotic and proliferative activity in the neoplastic progression of Barrett's esophagus: A comparative study
138. Molecular biology of Barrett's adenocarcinoma
139. Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma
140. Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer
141. Mechanisms of inactivation of p14ARF, p15INK4b and p16INK4a genes in human esophageal squamous cell carcinoma
142. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: A follow-up study
143. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK 4a locus deletion impairs both the Rb and p53 tumor suppressor pathway
144. Adenocarcinomas of the esophagus and gastric cardia: Medical conditions, tobacco, alcohol and socioeconomic factors
145. Barrett's esophagus: Metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma
146. FHIT gene alterations in esophageal cancer and ulcerative colitis